In a report released today, David Amsellem from Piper Sandler maintained a Buy rating on Amneal Pharmaceuticals (AMRX – Research Report), with ...

Try Now>> See the top stocks recommended by analysts >> Read More on AMRX: Amneal Pharmaceuticals NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

Amneal Pharmaceuticals (NYSE:NASDAQ:AMRX), a commercial-stage biopharmaceutical company with a market capitalization of $2.53 billion, has been positioning itself for a new phase of multi-year ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today ...

In trading on Monday, shares of Amneal Pharmaceuticals Inc (Symbol: AMRX) crossed below their 200 day moving average of $7.76, changing hands as low as $7.68 per share. Amneal Pharmaceuticals Inc ...

Amneal Pharmaceuticals (AMRX) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the ...

Chicago, IL – February 3, 2025 – Today, Zacks Equity Research discusses Corcept Therapeutics CORT, Amneal Pharmaceuticals AMRX, Dyne Therapeutics DYN, Nektar Therapeutics NKTR and Cardiol ...

It is worth considering Amneal Pharmaceuticals (AMRX), which belongs to the Zacks Medical - Drugs industry. When looking at the last two reports, this pharmaceutical company has recorded a strong ...

Daly, chief legal officer of Amneal Pharmaceuticals and the recipient of Corporate Counsel’s 2024 Mentor of the Year Award. “True leadership is about putting others first,” Daly told ...